Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 5Lymphoma 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Recurrence 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Mucositis 2Lymphoma, T-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Stomatitis 1Sezary Syndrome 1Sarcoma 1Primary Myelofibrosis 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms, Neuroepithelial 1Myeloproliferative Disorders 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × Fibroblast Growth Factor 7 × Clear all
NCT01237951 2020-05-05

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
75 enrolled 11 charts
Plasma cell

Neoplasms, Plasma Cell

NCT00410982 2016-06-03

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
145 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡